NO20075111L - Farmasoytisk sammensetning - Google Patents
Farmasoytisk sammensetningInfo
- Publication number
- NO20075111L NO20075111L NO20075111A NO20075111A NO20075111L NO 20075111 L NO20075111 L NO 20075111L NO 20075111 A NO20075111 A NO 20075111A NO 20075111 A NO20075111 A NO 20075111A NO 20075111 L NO20075111 L NO 20075111L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical composition
- quinazolineamines
- disordered
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67280505P | 2005-04-19 | 2005-04-19 | |
PCT/US2006/014447 WO2006113649A1 (en) | 2005-04-19 | 2006-04-18 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20075111L true NO20075111L (no) | 2007-11-16 |
Family
ID=37115487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20075111A NO20075111L (no) | 2005-04-19 | 2007-10-09 | Farmasoytisk sammensetning |
Country Status (28)
Country | Link |
---|---|
US (3) | US8821927B2 (es) |
EP (1) | EP1871347B1 (es) |
JP (1) | JP5202302B2 (es) |
KR (1) | KR101356748B1 (es) |
CN (1) | CN101203211B (es) |
AR (1) | AR054252A1 (es) |
AU (1) | AU2006236423B2 (es) |
BR (1) | BRPI0609962B1 (es) |
CA (1) | CA2606207C (es) |
CY (1) | CY1118179T1 (es) |
DK (1) | DK1871347T3 (es) |
EA (1) | EA200702253A1 (es) |
ES (1) | ES2601503T3 (es) |
HR (1) | HRP20161429T1 (es) |
HU (1) | HUE030982T2 (es) |
IL (1) | IL186336A0 (es) |
LT (1) | LT1871347T (es) |
MA (1) | MA29404B1 (es) |
MX (1) | MX2007013089A (es) |
NO (1) | NO20075111L (es) |
NZ (1) | NZ562223A (es) |
PE (1) | PE20061430A1 (es) |
PL (1) | PL1871347T3 (es) |
PT (1) | PT1871347T (es) |
SI (1) | SI1871347T1 (es) |
TW (1) | TW200716204A (es) |
WO (1) | WO2006113649A1 (es) |
ZA (1) | ZA200708705B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20061430A1 (es) * | 2005-04-19 | 2007-01-25 | Smithkline Beecham Cork Ltd | Composicion farmaceutica que comprende compuestos de 4-quinazolinaminas |
WO2009137714A2 (en) * | 2008-05-07 | 2009-11-12 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
EP2158912A1 (en) * | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
EP2158913A1 (en) | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
WO2010099150A1 (en) * | 2009-02-24 | 2010-09-02 | Smithkline Beecham (Cork) Limited | Pharmaceutical tablet and process |
WO2011039759A1 (en) * | 2009-09-29 | 2011-04-07 | Natco Pharma Limited | A new process for the preparation of lapatinib and its pharmaceutically acceptable salts |
WO2011146710A1 (en) | 2010-05-21 | 2011-11-24 | Glaxosmithkline Llc | Combination |
WO2011146712A1 (en) | 2010-05-21 | 2011-11-24 | Glaxosmithkline Llc | Combination |
BR112013002511A2 (pt) | 2010-08-03 | 2017-06-27 | Altherx Inc | combinações de agonistas de receptores adrenérgicos beta - 3 e antagonistas receptores muscarínicos para tratamento da bexica hiperativa |
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
ES2635620T3 (es) * | 2013-02-19 | 2017-10-04 | Hexal Ag | Composición farmacéutica que comprende n-[3-cloro-4-(3-fluorobenciloxi)fenil]-6-[5({[2-(metilsulfonil)etil]amino} metil)-2-furil]quinazolin-4-amina o una sal, solvato o sal solvatada farmacéuticamente aceptables de la misma |
WO2014170910A1 (en) | 2013-04-04 | 2014-10-23 | Natco Pharma Limited | Process for the preparation of lapatinib |
US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
CN107205964A (zh) | 2014-12-03 | 2017-09-26 | 威力塞帕特治疗股份有限公司 | 使用调节释放索拉贝隆用于下尿路症状的组合物和方法 |
CN106389373B (zh) * | 2015-07-29 | 2019-07-02 | 四川科伦药物研究院有限公司 | 一种二甲苯磺酸拉帕替尼片剂及其制备方法 |
CN106511289A (zh) * | 2015-09-10 | 2017-03-22 | 湖北生物医药产业技术研究院有限公司 | 甲苯磺酸拉帕替尼片剂及其制备方法 |
US10065922B2 (en) | 2015-10-23 | 2018-09-04 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
CZ296959B6 (cs) | 1997-04-25 | 2006-08-16 | Janssen Pharmaceutica N. V. | Chinazolon, zpusob a meziprodukt pro jeho výrobu a farmaceutický prostredek s jeho obsahem |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
DE60126611T2 (de) * | 2000-06-30 | 2007-11-22 | Glaxo Group Ltd., Greenford | Ditosylatsalze von chinazolinverbindungen |
DE60203260T2 (de) | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
US20050176740A1 (en) | 2002-04-08 | 2005-08-11 | Spector Neil L. | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
US20060094068A1 (en) | 2002-06-19 | 2006-05-04 | Bacus Sarah S | Predictive markers in cancer therapy |
PE20061430A1 (es) * | 2005-04-19 | 2007-01-25 | Smithkline Beecham Cork Ltd | Composicion farmaceutica que comprende compuestos de 4-quinazolinaminas |
-
2006
- 2006-04-18 PE PE2006000406A patent/PE20061430A1/es not_active Application Discontinuation
- 2006-04-18 ES ES06750475.3T patent/ES2601503T3/es active Active
- 2006-04-18 TW TW095113811A patent/TW200716204A/zh unknown
- 2006-04-18 CA CA2606207A patent/CA2606207C/en active Active
- 2006-04-18 EP EP06750475.3A patent/EP1871347B1/en active Active
- 2006-04-18 KR KR1020077026740A patent/KR101356748B1/ko active IP Right Grant
- 2006-04-18 LT LTEP06750475.3T patent/LT1871347T/lt unknown
- 2006-04-18 NZ NZ562223A patent/NZ562223A/en not_active IP Right Cessation
- 2006-04-18 JP JP2008507783A patent/JP5202302B2/ja active Active
- 2006-04-18 AU AU2006236423A patent/AU2006236423B2/en not_active Revoked
- 2006-04-18 MX MX2007013089A patent/MX2007013089A/es active IP Right Grant
- 2006-04-18 SI SI200632109A patent/SI1871347T1/sl unknown
- 2006-04-18 CN CN2006800219417A patent/CN101203211B/zh active Active
- 2006-04-18 US US11/911,843 patent/US8821927B2/en active Active
- 2006-04-18 BR BRPI0609962-9A patent/BRPI0609962B1/pt active IP Right Grant
- 2006-04-18 PL PL06750475T patent/PL1871347T3/pl unknown
- 2006-04-18 PT PT67504753T patent/PT1871347T/pt unknown
- 2006-04-18 HU HUE06750475A patent/HUE030982T2/en unknown
- 2006-04-18 EA EA200702253A patent/EA200702253A1/ru unknown
- 2006-04-18 DK DK06750475.3T patent/DK1871347T3/en active
- 2006-04-18 WO PCT/US2006/014447 patent/WO2006113649A1/en active Application Filing
- 2006-04-18 AR AR20060101526A patent/AR054252A1/es not_active Application Discontinuation
-
2007
- 2007-10-07 IL IL186336A patent/IL186336A0/en unknown
- 2007-10-09 NO NO20075111A patent/NO20075111L/no not_active Application Discontinuation
- 2007-10-11 ZA ZA200708705A patent/ZA200708705B/xx unknown
- 2007-10-25 MA MA30318A patent/MA29404B1/fr unknown
-
2014
- 2014-07-28 US US14/444,637 patent/US20140335177A1/en not_active Abandoned
-
2016
- 2016-01-29 US US15/009,927 patent/US20160143909A1/en not_active Abandoned
- 2016-11-02 HR HRP20161429TT patent/HRP20161429T1/hr unknown
- 2016-11-03 CY CY20161101115T patent/CY1118179T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20075111L (no) | Farmasoytisk sammensetning | |
NO20170633A1 (no) | Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff . | |
WO2006086562A3 (en) | Phenylazetidinone derivatives | |
LTC1781298I2 (lt) | Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui | |
NO20081592L (no) | Dipeptidylpeptidaseinhibitorer for behandling av diabetes | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
CY1112889T1 (el) | Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης | |
IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
TW200716628A (en) | Novel compounds | |
EA200970273A1 (ru) | Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила | |
NO20090175L (no) | Stabile laquinimod sammensetninger | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
DK1863812T3 (da) | Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler | |
NO20064078L (no) | Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter | |
MY140514A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
ECSP088763A (es) | Nuevas combinaciones terapéuticas para el tratamiento de la depresión | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
ATE350377T1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
NO20083250L (no) | Antibakterielle pyrrolopyridiner, pyrrolopyrimidiner og pyrroloazepiner | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
NO341679B1 (no) | Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren | |
WO2009071689A3 (de) | 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |